El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

jcm-11-01611-v2.pdf (1.23 MB)

Tipus de document

Article

Data de publicació

2022-03-17

Llicència de publicació

cc by (c) Bonanad, Clara et al, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/185022

Evaluation of the Use of Dual Antiplatelet Therapy beyond the First Year after Acute Coronary Syndrome

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm11061680

Resum

Clinical practice guidelines recommend extending dual antiplatelet therapy (DAPT) beyond 1 year after acute coronary syndrome (ACS) in patients with high ischemic risk and without high bleeding risk. The aim of this study was to identify variables associated with DAPT prolongation in a cohort of 1967 consecutive patients discharged after ACS without thrombotic or hemorrhagic events during the following year. The sample was stratified according to whether DAPT was extended beyond 1 year, and the factors associated with this strategy were analyzed. In 32.2% of the patients, DAPT was extended beyond 1 year. Overall, 770 patients (39.1%) were considered candidates for extended treatment based on PEGASUS criteria and absence of high bleeding risk, and DAPT was extended in 34.4% of them. The presence of a PEGASUS criterion was associated with extended DAPT in the univariate analysis, but not history of bleeding or a high bleeding risk. In the multivariate analysis, a history of percutaneous coronary intervention (odds ratio (OR) = 1.8, 95% confidence interval (CI) 1.4-2.4), stent thrombosis (OR = 3.8, 95% CI 1.7-8.9), coronary artery disease complexity (OR = 1.3, 95% CI 1.1-1.5), reinfarction (OR = 4.1, 95% CI 1.6-10.4), and clopidogrel use (OR = 1.3, 95% CI 1.1-1.6) were significantly associated with extended use. DAPT was extended in 32.2% of patients who survived ACS without thrombotic or hemorrhagic events. This percentage was 34.4% when the candidates were analyzed according to clinical guidelines. Neither the PEGASUS criteria nor the bleeding risk was independently associated with this strategy.

Matèries

Malalties coronàries, Isquèmia

Matèries (anglès)

Coronary diseases, Ischemia

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BONANAD, Clara, RAPOSEIRAS ROUBÍN, Sergio, GARCÍA BLAS, Sergio, NÚÑEZ GIL, Iván, VERGARA UZCATEGUI, Carlos, DÍEZ VILLANUEVA, Pablo, BAÑERAS, Jordi, BADÍA MOLINS, Clara, ABOAL, Jaime, CARRERAS, Jose, BODI, Vicente, GABALDÓN PÉREZ, Ana, MATEUS PORTA, Gemma, PARADA BARCIA, Jose antonio, MARTÍNEZ SELLÉS, Manuel, CHORRO, Francisco javier, ARIZA SOLÉ, Albert. Evaluation of the Use of Dual Antiplatelet Therapy beyond the First Year after Acute Coronary Syndrome. _Journal of Clinical Medicine_. 2022. Vol. 11, núm. 6. [consulta: 1 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/185022]

Exportar metadades

JSON - METS

Compartir registre